dabigatran has been researched along with Coronary Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
| Böhm, M; Brueckmann, M; Connolly, S; Eikelboom, JW; Ewen, S; Ezekowitz, M; Millenaar, D; Schumacher, H; Slawik, J; Ukena, C; Wallentin, L; Yusuf, S | 1 |
| Mohebbi, N | 1 |
| Nendaz, M; Perrier, A | 1 |
1 review(s) available for dabigatran and Coronary Disease
| Article | Year |
|---|---|
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2018 |
3 other study(ies) available for dabigatran and Coronary Disease
| Article | Year |
|---|---|
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Coronary Disease; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Polypharmacy; Proportional Hazards Models; Stroke; Warfarin | 2021 |
[Update in hospital internal medicine (2007): a selection].
Topics: Anti-Bacterial Agents; Anticoagulants; Benzimidazoles; Bone Density Conservation Agents; Community-Acquired Infections; Coronary Disease; Dabigatran; Defibrillators, Implantable; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Heart Neoplasms; Hip Prosthesis; Hospital Departments; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Internal Medicine; Liver Cirrhosis; Oligosaccharides; Osteoporosis; Peritonitis; Pneumonia, Bacterial; Pulmonary Embolism; Pyridines; Quality of Health Care; Risk Factors; Stroke; Teaching; Tomography, X-Ray Computed; Venous Thrombosis | 2008 |